1,557
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Six-cell penetrating peptide-based fusion proteins for siRNA delivery

&
Pages 436-443 | Received 05 Dec 2013, Accepted 06 Jan 2014, Published online: 04 Feb 2014

References

  • Aliabadi HM, Landry B, Sun C, et al. (2012). Supramolecular assemblies in functional siRNA delivery: where do we stand? Biomaterials 33:2546–69
  • Baoum A, Ovcharenko D, Berkland C. (2012). Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. Int J Pharmaceut 427:134–42
  • Bycroft M, Grünert S, Murzin AG, et al. (1995). NMR solution structure of a dsRNA binding domain from Drosophila staufen protein reveals homology to the N-terminal domain of ribosomal protein S5. EMBO J 14:3563–71
  • Choi J-M, Ahn M-H, Chae W-J, et al. (2006). Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 12:574–9
  • Choi J-M, Kim S-H, Shin J-H, et al. (2008). Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. Proc Nat Acad Sci USA 105:19875–80
  • Doyle M, Jantsch MF. (2003). New and old roles of the double-stranded RNA-binding domain. J Struct Biol 140:147–53
  • Dykxhoorn DM, Palliser D, Lieberman J. (2006). The silent treatment: siRNAs as small molecule drugs. Gene Therapy 13:541–52
  • Eguchi A, Akuta T, Okuyama H, et al. (2001). Protein Transduction Domain of HIV-1 Tat Protein Promotes Efficient Delivery of DNA into Mammalian Cells. J Biol Chem 276:26204–10
  • Eguchi A, Meade BR, Chang Y-C, et al. (2009). Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27:567–71
  • El-Andaloussi S, Johansson HJ, Holm T, et al. (2007). A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther 15:1820–6
  • Endoh T, Ohtsuki T. (2009). Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Advanced Drug Deliv Rev 61:704–9
  • Gan J, Tropea JE, Austin BP, et al. (2005). Intermediate states of ribonuclease III in complex with double-stranded RNA. Structure 13:1435–42
  • Haupenthal J, Baehr C, Kiermayer S, et al. (2006). Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol 71:702–10
  • Jantsch MF. (1996). Comparative mutational analysis of the double-stranded RNA binding domains of Xenopus laevis RNA-binding protein A. J Biol Chem 271:28112–19
  • Kharrat A, Macias MJ, Gibson TJ, et al. (1995). Structure of the dsRNA binding domain of E. coli RNase III. EMBO J 14:3572–84
  • Koppelhus U, Shiraishi T, Zachar V, et al. (2008). Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. Bioconjugate Chem 19:1526–34
  • Lee SH, Castagner B, Leroux J-C. (2013). Is there a future for cell-penetrating peptides in oligonucleotide delivery? Eur J Pharmaceut Biopharm Offic J Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 85:5–11
  • Lee YW, Kim WT. (2010). Tobacco GTBP1, a homolog of human heterogeneous nuclear ribonucleoprotein, protects telomeres from aberrant homologous recombination. Plant Cell 22:2781–95
  • Li S-D, Huang L. (2007). Non-viral is superior to viral gene delivery. J Control Release 123:181–3
  • Lindgren M, Gallet X, Soomets U, et al. (2000). Translocation properties of novel cell penetrating transportan and penetratin analogues. Bioconjugate Chem 11:619–26
  • Meade BR, Dowdy SF. (2007). Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 59:134–40
  • Meade BR, Dowdy SF. (2008). Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Advanced Drug Deliv Rev 60:530–6
  • Mo RH, Zaro JL, Shen W-C. (2012). Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol pharmaceut 9:299–309
  • Nakase I, Takeuchi T, Tanaka G, et al. (2008). Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Delivery Rev 60:598–607
  • Nanduri S, Carpick BW, Yang Y, et al. (1998). Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J 17:5458–65
  • Palm-apergi C, Eguchi A, Dowdy SF. (2011). PTD–DRBD siRNA delivery. Methods Mol Biol 683:339–47
  • Raemdonck K, Vandenbroucke RE, Demeester J, et al. (2008). Maintaining the silence: reflections on long-term RNAi. Drug Discov Today 13:917–31
  • Ramos A, Bayer P, Varani G. (1999). Determination of the structure of the RNA complex of a double-stranded RNA-binding domain from Drosophila Staufen protein. Biopolymers 52:181–96
  • Veldhoen S, Laufer SD, Trampe A, et al. (2006). Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 34:6561–73

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.